Presentation Information
[BO-2]A common deletion at BAK1 attenuates enhancer activity and confers risk of intracranial germ cell tumors
○Kyuto Sonehara1, Yui Kimura2,3, Yoshiko Nakano3,4, Tatsuya Ozawa3, Meiko Takahashi5, Ken Suzuki1, Takashi Fujii6,7,8, Yuko Matsushita7,8, Arata Tomiyama6,7,8, Toshihiro Kishikawa1,9, Kenichi Yamamoto1, Tatsuhiko Naito1,10, Tomonari Suzuki11, Shigeru Yamaguchi12, Tomoru Miwa13, Hikaru Sasaki13, Masashi Kitagawa14, Naoyuki Ohe15, Junya Fukai16, Hideki Ogiwara2, Atsufumi Kawamura17, Satoru Miyawaki18, Fumihiko Matsuda5, Nobutaka Kiyokawa2, Koichi Ichimura3,8, Ryo Nishikawa11, Yukinori Okada1,10,19,20, Keita Terashima2 (1.Osaka University Graduate School of Medicine, Suita, Japan, 2.National Center for Child Health and Development, Tokyo, Japan, 3.National Cancer Center Research Institute, Tokyo, Japan, 4.The University of Tokyo Hospital, Tokyo, Japan, 5.Kyoto University Graduate School of Medicine, Kyoto, Japan, 6.National Defense Medical College, Tokorozawa, Japan, 7.Juntendo University School of Medicine, Tokyo, Japan, 8.Graduate School of Medicine, Juntendo University, Tokyo, Japan, 9.Aichi Cancer Center Hospital, Nagoya, Japan, 10.Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, 11.Saitama Medical University International Medical Center, Hidaka, Japan, 12.Faculty of Medicine, Hokkaido University, Sapporo, Japan, 13.Keio University School of Medicine, Tokyo, Japan, 14.Shizuoka Children's Hospital, Shizuoka, Japan, 15.Graduate School of Medicine, Gifu University, Gifu, Japan, 16.Wakayama Medical University School of Medicine, Kimiidera, Japan, 17.Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, 18.Faculty of Medicine, the University of Tokyo, Tokyo, Japan, 19.Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan, 20.RIKEN Center for Integrative Medical Sciences, Yokohama, Japan)